Joint Program Executive Office for Chemical and Biological Defense
061215_CBDAIF_Briefing 1
STEPHEN V. REEVESMajor General, USA
Joint Program Executive Officerfor Chemical and Biological Defense
(703) 681-9600
Chemical Biological Defense Acquisition Initiatives Forum
December 15, 2006
Distribution Statement A: Approved for Public Release
UNCLASSIFIED
Joint Program Executive Office for Chemical and Biological Defense
2061215_CBDAIF_Briefing UNCLASSIFIED
Updates
• Congressional Outlook – FY08 Budget
• Lean Six Sigma
• EVMS Policy
• BARDA
• Industry Security Clearances
• Biosurety Regulations
• Experimentation in Requirements Definition
• Contracting Opportunities
• Upcoming Events
Joint Program Executive Office for Chemical and Biological Defense
3061215_CBDAIF_Briefing UNCLASSIFIED
Congressional Outlook
• FY 08 President’s Budget Submission
• Budget Drivers
– War Costs / O&M Bills
– Supplementals
– Tri-Care for Life
• Congressional Budget Adds to CBDP
FY03 + 400M FY07 – 44M
Joint Program Executive Office for Chemical and Biological Defense
4061215_CBDAIF_Briefing UNCLASSIFIED
Lean Six Sigma
• Key Element of DoD Business Transformation
• Applies Quantitative Methods to Process Improvement
• Lean Six Sigma Technique Deployed Through-out Services
Joint Program Executive Office for Chemical and Biological Defense
5061215_CBDAIF_Briefing UNCLASSIFIED
Earned Value Management Thresholds
• DoD Revised Earned Value Management System (EVMS) Contract Thresholds in March 2005– A Validated EVMS is Required for Contracts Over $50M
– A Tailored EVMS is Required for Contracts From $20M - $50M
– EVMS is Optional for Contracts Less Than $20M – Project Manager Decides Based on Business Case Analysis
• EVMS is Based on Industry Standard ANSI/EIA 748
• Work Breakdown Structure, Contract Performance Reporting and Integrated Master Schedule Also Required with EVMS
References:OSD EVM Web Site: http://www.acq.osd.mil/pm/
EVM Community of Practice: https://acc.dau.mil/evm
References:OSD EVM Web Site: http://www.acq.osd.mil/pm/
EVM Community of Practice: https://acc.dau.mil/evm
Joint Program Executive Office for Chemical and Biological Defense
6061215_CBDAIF_Briefing UNCLASSIFIED
Biomedical Advanced Research and Development Authority (BARDA)
• Biodefense and Pandemic Vaccine and Drug Development Act of 2006 (HR 5533)
– Establishes the Biomedical Advanced Research and Development Authority (BARDA) within DHHS
– Designates BARDA as the Single Federal Authority with the Core Mission of Heading Off a Public Health Catastrophe (Epidemic, Pandemic or Bioterrorism) Through Coordinated Research and Development Activities for Countermeasures to Bioterrorism and Pandemic Influenza
– Authorizes One or More Federally-funded Research and Development Centers, or University-Affiliated Research Centers
– Status: Pending Joint House and Senate Conference
Joint Program Executive Office for Chemical and Biological Defense
7061215_CBDAIF_Briefing UNCLASSIFIED
BARDA and BioShield
BARDA
• BARDA Focuses Solely to Promote Advanced Research & Development of Bioterrorism/ Pandemic Countermeasures
• BARDA Overseen by DHHS
BioShield
• H.R. 5533 Clarifies Project BioShield as a Program that Provides Incentives to Companies to Manufacture Vaccines and Drugs
• BioShield Covers Certain Products (e.g., qualified and security countermeasures) that Address Public Health Threats Caused by Acts of Terrorism.
• Project BioShield Expedites National Institutes of Health (NIH) R&D Efforts
– Allows FDA to Make Countermeasures Available During an Emergency
– Allows the Federal Government to Procure and Maintain Medical Countermeasure Supplies (DHS, $5.6B over 10 yrs)
– Overseen by DHS and DHHS
Joint Program Executive Office for Chemical and Biological Defense
8061215_CBDAIF_Briefing UNCLASSIFIED
CBDP and BARDA
• BARDA Provides an Opportunity to Leverage and Synchronize Medical Countermeasure Investments
• CBDP Should Coordinate with DHHS in the Development of the DHHS Strategic Plan for Consideration of DoD Opportunity Savings and Synchronization
• BARDA May Be Used to Leverage TMTI Countermeasure Investments, Especially FDA Approaches
Joint Program Executive Office for Chemical and Biological Defense
9061215_CBDAIF_Briefing UNCLASSIFIED
GAO Report on Security Clearances
• Industry Personnel Hold 34% of 2.5 Million DoD Clearances
• Office of Personnel Management Investigates
• GAO Found for Top Secret Clearances:
– 446 Days Required for Initial Clearance
– 545 Days Required for Clearance Update
• GAO Recommended:
– More Accurate Measurement of Process Time
– Use of Information Technology Solutions
– Update the Plan to Improve the Process
– Metrics to Monitor Effectiveness of New Procedures
Joint Program Executive Office for Chemical and Biological Defense
10061215_CBDAIF_Briefing UNCLASSIFIED
Speeding Clearances - Reducing Backlog
• All Investigations Placed Under OPM
• OPM Added More Investigators
• Closer OPM Coordination with Records Agencies
• Resumed Industry Submissions July 2006
• DoD Increasing Electronic Submissions (eQIP)
• Additional DoD Positions Added to Reduce Adjudication Time
• Additional Defense Security Service Funding
Joint Program Executive Office for Chemical and Biological Defense
11061215_CBDAIF_Briefing UNCLASSIFIED
Biosurety Regulations Update
• DoD Directive 5210.88 Safeguarding Biological Select Agents and Toxins. February 2004
• DoD Instruction 5210.89 Minimum Security Standards for Safeguarding Biological Select agent and Toxins. April 2006
• Army Regulation 190-17, Biological Select Agents and Toxins Security Program. October 2006
• Draft Army Regulation 50-X Biological Surety. Coordinating with OSD to Minimize Disparities with DoD Directive. (Pending Legal Review)
Guidance and Information for Industry at: http://www.dss.mil/index.htm
Joint Program Executive Office for Chemical and Biological Defense
061215_CBDAIF_Briefing 12
Using Experimentation to Define Requirements/Concepts of Use
Joint Program Executive Office for Chemical and Biological Defense
13061215_CBDAIF_Briefing UNCLASSIFIED
Joint CBRN Dismountable Reconnaissance System Limited Objective Experiment (JCDRS LOE) Phase III
Modular Concept
Definition• Employment of Mature, Enabling Technologies (Plug-n-Play,
Interface Standards, Wireless, GPS, …) to Provide Net-centric and Modular Capability
• Integrated Components Designed for Mounted and Dismounted Operation
• Standardization of Data Formats, Communications Protocols, and Sensor/Hardware Packaging
Benefits• Easier CBRN Integration into Platforms• Tailorable CBRN Defense Capability• Increased Standardization of CBRN Equipment • Easily Upgraded Systems• Net-Centric Architecture: Easily Accessed Data, Shared
Awareness, Increased Speed of Command, and Remote Access to Systems
Joint Program Executive Office for Chemical and Biological Defense
14061215_CBDAIF_Briefing UNCLASSIFIEDJC
ID O
n A
Ch
ip
Net-C
entric
Joint Program Executive Office for Chemical and Biological Defense
15061215_CBDAIF_Briefing UNCLASSIFIED
Opportunities Description Dates
Joint Service Light NBC Reconnaissance Vehicle
•Production RFP 2QFY07
Joint Chemical Agent Detector
• FY08 SBIR 1QFY08
Joint Biological Tactical Detection System
•RFP - Technology Demonstration of Tactical Bio System Capability
4QFY08
Joint Biological Standoff Detection System
•Technology Readiness Assessment FY08
Joint Expeditionary Collective Protection System (JECP)
• Initial Increment - RFP for Prime Contractor
1QFY07
SPAWAR Knowledge Superiority
•BAA N00039-05-X-0011 Continual
JWARN Component Interface Device
•Production FY08
Near Term Industry JPEO Opportunities
Joint Program Executive Office for Chemical and Biological Defense
16061215_CBDAIF_Briefing UNCLASSIFIED
Near Term Industry JPEO Opportunities (Cont’d)
Opportunities Description Dates
Joint Modular Decon System
•Capability for Platform Interior and Sensitive Item Decontamination
2QFY07
Joint Service Tactical Decon System – Large Scale
•RFP Release for R&D/Test Quantities FY08
Joint Platform Decon System
•Expected RFP Release for Increment 1 R&D/Test Quantities
FY08
Joint Chemical Ensemble •RDT&E - Next Generation Protective Ensemble
FY08
Installation Protection Plan Recompete
•Draft SOW Available for Comment at:http://www.jpeocbd.osd.mil/page_manager.asp?pg=3
TBD
Near Term Industry JPEO Opportunities (Cont’d)
Joint Program Executive Office for Chemical and Biological Defense
17061215_CBDAIF_Briefing UNCLASSIFIED
JPEO Medical Program Business Opportunities
Opportunities Description Dates
MITS
Medical Radiation Countermeasures RFP for Prime Contractor 1QFY07
JVAP – Subcontract Through DVC
Venezuelan Equine Encephalitis (VEE) Vaccine NIAID-funded Phase 2 Clinical Trial 4QFY07
Recombinant Botulinum (rBot) A/B Vaccine
Clinical Site Management for rBot Vaccine Phase 1B Clinical Trial 1QFY07
Joint Program Executive Office for Chemical and Biological Defense
18061215_CBDAIF_Briefing UNCLASSIFIED
Chemical Biological Information Systems Conference
• When: January 8 – 11, 2007
• Where: Austin, TX, Renaissance Austin Hotel
Joint Program Executive Office for Chemical and Biological Defense
19061215_CBDAIF_Briefing UNCLASSIFIED
Advanced Planning Briefing for Industry
• When: April 4 – 5, 2007
• Where: Washington DC Convention Center
• Format:
– Day 1
• JPM/CAPO Joint Brief
– Day 2
• JPM/ CAPO “1 on 1” with Industry
Joint Program Executive Office for Chemical and Biological Defense
20061215_CBDAIF_Briefing UNCLASSIFIED
Joint Program Executive Office for Chemical and Biological Defense
061215_CBDAIF_Briefing 21
BACKUPS
Joint Program Executive Office for Chemical and Biological Defense
22061215_CBDAIF_Briefing UNCLASSIFIED
Earned Value Management Requirements
• Cost or Incentive Type Contract Greater Than $50M– Compliance with Industry EVM Standard - ANSI/EIA 748
– Formal EVMS Validation by DCMA
– Cost Performance Report
– Integrated Master Schedule
– Integrated Baseline Review
– Ongoing Surveillance by DCMA
• Cost or Incentive Type Contract Greater Than $20M and Less Than $50M– Compliance with Industry EVM Standard
– No Formal EVMS Validation
– Cost Performance Report
– Tailored Integrated Master Schedule
– Integrated Baseline Review
– Ongoing Surveillance by DCMA
Joint Program Executive Office for Chemical and Biological Defense
23061215_CBDAIF_Briefing UNCLASSIFIED
Earned Value Management Requirements (Cont’d)
• Cost or Incentive Type Contract Less Than $20M
– EVMS is Optional
– Business Case Required to Justify EVM
Applying EVM to FFP Contracts is Strongly Discouraged
Joint Program Executive Office for Chemical and Biological Defense
24061215_CBDAIF_Briefing UNCLASSIFIED
Biomedical Advanced Research and Development Authority (BARDA)
• Through BARDA, DHHS will Coordinate and Oversee the Acceleration of Medical Countermeasure and Advanced Research and Development by:
– Facilitating Collaboration Among DHHS, Other Federal Agencies, Relevant Industries, and Academia
– Facilitating Contacts and Coordinating Efforts to Improve Process and Requirements Under the Federal Food, Drug, and Cosmetic Act
– Promoting Innovation to Reduce the Time and Cost of Countermeasure and Product Advanced Research and Development
Joint Program Executive Office for Chemical and Biological Defense
25061215_CBDAIF_Briefing UNCLASSIFIED
Biomedical Advanced Research and Development Authority (BARDA)
• Rationale:
– The Lack of Commercial Demand for Certain Medical Countermeasures has Discouraged Development and Created a Funding Gap Between Early Research and Transition Investment to Licensure
– BARDA Intends to Bridge That Gap By:
• Providing Interim Funding at Key Development Milestones
• Offer Grants, Awards Through Other Transaction Authority, and Prizes to Industry to Provide Incentives to Develop Certain Countermeasures Deemed Priorities
• Encourage Companies to Pursue Medicines Showing Promise in Early Research
Joint Program Executive Office for Chemical and Biological Defense
26061215_CBDAIF_Briefing UNCLASSIFIED
Biomedical Advanced Research and Development Authority (BARDA)
BARDA Requires DHHS to:
• Develop a Strategic Plan to Identify Biological and Infectious Disease Threats
• Evaluate Research and Development Opportunities
• Conduct Annual Outreach and Working Groups
• Funding– Authorizes the appropriation of $160 million for each of fiscal years
2007 and 2008 for activities related to the operation of BARDA.
– The bill also would authorize the appropriation of $1 million for each of fiscal years 2007 and 2008 for the National Biodefense Science Board.
– Congressional Budget Office (CBO) estimates that $1 million a year would be necessary for FDA to implement activities outlined in the bill.
– Assuming appropriation of the authorized and necessary amounts, CBO estimates that implementing H.R. 5533 would cost $33 million in 2007 and $319 million over the 2007-2011 period.
Joint Program Executive Office for Chemical and Biological Defense
27061215_CBDAIF_Briefing UNCLASSIFIED
Installation Protection Program (IPP)
• Industry is Invited to Comment on a Draft IPP Statement of Work (SOW)
• This Provides JPM Guardian Information to Improve the SOW for any Upcoming Procurements
• The SOW is Available at:
http://www.jpeocbd.osd.mil